San Diego-centered Viking Therapeutics marked alone as a significant competitor during the weight loss drug market place in February after revealing promising details from a mid-stage trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided as a weekly injection As well as in March the